Positioning Statements on Physician-led Switching for Biosimilar Medicines

Related Posts

• EMA/HMA share definitive EU-wide position on biosimilar… 19 September 2022 The Biosimilar medicines group, a Medicines for Europe sector group,…
• Medicines for Europe Position Paper on Bolar Exemption - Feb… 15 February 2021 Open
• Medicines for Europe Position on IP Action Plan - March 2021 13 March 2021 Open
• European patients need improved access to biosimilar… 22 April 2021 Fifteen years after the first global approval, biosimilar medicines systemically…